CURRICULUM VITAE: **MARK T. CLAUS, M.D.**

EMPLOYMENT:

Asthma & Allergy Physicians
35 Pearl Street, Suite 300
Brockton, MA 02301
1988 - Present

Sub-Investigator - Center For Clinical Research
Center For Clinical Research
35 Pearl Street, Suite 300
Brockton, MA 02301
1991 - Present

EDUCATION:

Boston University, B.A.
9/76 - 8/78

Boston University School of Medicine, M.D.
9/78 - 5/82

GRADUATE MEDICAL EDUCATION:

University of Massachusetts Medical Center
Pediatric Residency
7/82 - 6/84

L. I. Jewish-Hillside Medical Center
Pediatric Residency
7/84 - 6/86

Nassau County Medical Center/North Shore
University Hospital
Allergy/Immunology Fellowship
7/86 - 6/88

HONORS/AWARDS:

Graduated-Summa Cum Laude
Honors Achieved in Medical School Core
Curriculum-Physiology, Nutrition and Epidemiology

Travel Grant Award - American College of
Allergists - 44th Annual Congress
November, 1987 in Boston, MA

Travel Grant Award - American College of
Allergists - 44th Annual Meeting
March, 1988 in Anaheim, CA

Revised 04/23/2018

LICENSURE: Commonwealth of Massachusetts #59634
June 21, 1988

MEMBERSHIPS: American College of Allergy, Asthma & Immunology
American Medical Association
Massachusetts Medical Society

PUBLICATIONS: VI International Food Allergy Symposium in Boston, MA., on November 13, 1987, Lymphocyte Proliferative Response to Food Antigens in Crohn's Disease.

44th Annual Congress of the American College of Allergists in Boston, MA, on November 15, 1987, Humoral Immunity in Crohn's Disease.

44th Annual Meeting of the American Academy and Immunology in Anaheim, CA, on March 12, 1988, Cell Surface Marker Analysis by Flow Cytometry in Crohn's Disease.

Pediatric Mastocytosis Presenting with Shock, Hemorrhagic Bullae and Gastritis-Abstract, Annals of Allergy

Frieri, M., Claus, M., Santiago, M., Annunziator, D., and Sujatha, j., Lin, J., "Fever, Hemorrhagic Bullae and Gastritis in a 20 month old male" Annals of Allergy 63: 179, 1989.

Frieri, M., Claus, M., Bors, M., Zitt, M., Scalise, D., Harris, N., "Preliminary Investigation on Humoral and Cellular Immune Responses to Selected Food Protein in Patients with Crohns Disease." Annals of Allergy 64: 345, 1990.

CLINICAL RESEARCH TRIALS:

2015 A Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects with a History of House Dust Mite-Induced Rhinoconjunctivitis.
Protocol No. TH005. Circassia Ltd.

2015 A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on inhaled Corticosteroid Plus Long-Acting B2-Agonist. (STRATOS 1)
Study No. D2210C00007. AstraZeneca AB

2014 A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and

	Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 years of Age and Older with Persistent Asthma Protocol No. FSS-AS-305. Teva Branded Pharmaceutical Products R&D, Inc.
2014	Long-Term Natural History of Patients with Severe or Difficult-to-Treat Asthma from the TENOR Observational Study. Study No. CIGE025BUS28/TENOR II. Novartis Pharmaceuticals Corporation.
2013	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication. Protocol No. GB28689. Genentech F. Hoffman-LaRoche; LTD.
2013	Prospero - A Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab. Protocol No. ML28528. Genentech.
2013	A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects with House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001-00). Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2012	A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Subjects with Severe Persistent Asthma Uncontrolled on High dose Inhaled Corticosteroid Therapy. 6 Subjects. Protocol No. FpS-AS-202. Teva Branded Pharmaceutical Products R&D, Inc.
2012	A Phase IIb, Randomized Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of … in Patients with Uncontrolled Asthma Who Are On Inhaled Corticosteroids And A Second Controller Medication. Protocol Number: GB27864, Version Number 3. F. Hoffmann-La Roche, Ltd.
2011	A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum pratense) Sublingual Tablet (SCH 697243) in Subjects Between 5 and 65 Years of Age, With a History of Grass Pollen-Induced Rhinoconjunctivitis, With or Without Asthma (Protocol No. P08067). Schering-Plough Research Institute. 5579981.
2011	A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of … …/… … MDI Fixed Dose Combination

	Versus … … MDI Monotherapy in Adolescents and Adults With Persistent Asthma. (Protocol No. P06241 also known as P202). Schering-Plough Research Institute.
2010	A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of … …Compared with Placebo for 12 Weeks in Patients with Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the 2 … … Doses. Forest Research Institute, Inc. LAS-MD-38.
2010	A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Persistency of Response With or Without XOLAIR after Long-Term Therapy (XPORT). Q4777n.
2010	A Multicenter-Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects with a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma. Schering-Plough Research Institute. P05234.
2009	A 52-week treatment, randomized, double-blind, placebo-controlled, with open label … , parallel-group study to assess the efficacy, safety and tolerability of NVA237 in patients with chronic obstructive pulmonary disease. Novartis, CNVA237A2303. Version 2.
2008	Placebo-Controlled Study of …… Nasal Spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Associated with Seasonal Allergic rhinitis (SAR). Schering-Plough Research Institute, P05529.
2008	Developmental Study Protocol Test for Respiratory and Asthma Control in Kids (TRACK). Amendment December 6, 2007, Version 3. QualityMetric, Inc., TRACK Developmental Portocol.
2007	Efficacy and Safety of Concurrent Administration of … … Nasal Spray (MFNS) and … Nasal Spray Administered Once Daily (QD) vs. … Twice Daily (B.I.D.), … … QD, and Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis. Schering-Plough Research Institute, P04500.
2007	A Study in the Therapeutic Equivalency of MF DPI 100 mcg and 200 mcg Inhalers in Corticosteroid-Dependent Subjects with Moderate Asthma. Schering-Plough Research Institute, P04828.
2007	A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair® in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-

	Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists. Genentech, Inc., Q3662g, Amendment #2.
2006	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Stratified, Multi-center, 12-week study Comparing the Safety and efficacy of … and … Combination (… 100/10ug or 250/10ug twice daily) in a Single Inhaler (… HFA pMDI) with the Administration of Placebo or … (250ug twice daily) and … (10ug twice daily) Alone in Adolescent and Adult Patients with Moderate to Severe Asthma. 8 Subjects. SkyePharma Protocol SKY2028-3-004.
2006	A Multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of … metered-dose inhaler at a daily dose of 160ug administered either in a once-daily in the morning regimen (160ug qd AM) for 16 weeks or in a 160ug qd AM regimen for 12 weeks preceded by a twice-daily regimen (80ug bid) for 4 weeks, or in an 80 ug regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids. 6 Subjects. Sanofi-Aventis XRP1526B/3031.
2006	A Multicenter, Double-Blind, Placebo Controlled, Randomized, Parallel-Group Study to Evaluate the Clinical Effect of Oral … Versus Placebo in Persistent Asthma Which 2005 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of "…" Aqueous Nasal Spray 50 mcg. and 100 mcg. for 2 Weeks in Pediatric Subjects Ages 2 to <12 Years with Seasonal Allergic Rhinitis (SAR). 8 Subjects. The GlaxoSmithKline Group of Companies, Protocol #FFR100010.
2005	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of "…" Aqueous Nasal Spray 100 mcg. for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor/Idiopathic Rhinitis. 10 Subjects. The GlaxoSmithKline Group of Companies, Protocol #FFR30007.
2005	A 12-Month Double-blind, Double-Dummy, Randomized, Parallel group, Multicenter Efficacy and Safety Study of "…" pMDI 2x 160/4.5 µg b.i.d. and 2 x 80/4.5 µg b.i.d. Compared to … TBH 2 x 4.5 µg b.i.d. and Placebo in Patients with COPD. 6 Subjects. AstraZeneca, Protocol #D5899C00001.
2005	A 6-Month Double-blind, Double-dummy, Randomized, Parallel group, Multicenter Efficacy and Safety Study of "…" pMDI 2 x 160/4.5 µg & 80/4.5 µg b.i.d. Compared to … TBH, … pMDI (& the combination & Placebo in COPD Patients. 6 Subjects. AstraZeneca, Protocol #D5899C00002.

2005	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of "…" Aqueous Nasal Spray 50 mcg. and 100 mcg. for 2 Weeks in Pediatric Subjects Ages 2 to <12 Years with Seasonal Allergic Rhinitis (SAR). 8 Subjects. The GlaxoSmithKline Group of Companies, Protocol #FFR100010.
2005	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of "…" Aqueous Nasal Spray 100 mcg. for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor/Idiopathic Rhinitis. 10 Subjects. The GlaxoSmithKline Group of Companies, Protocol #FFR30007.
2005	A 12-Month Double-blind, Double-Dummy, Randomized, Parallel group, Multicenter Efficacy and Safety Study of "…" pMDI 2x 160/4.5 µg b.i.d. and 2 x 80/4.5 µg b.i.d. Compared to … TBH 2 x 4.5 µg b.i.d. and Placebo in Patients with COPD. 6 Subjects. AstraZeneca, Protocol #D5899C00001.
2005	A 6-Month Double-blind, Double-dummy, Randomized, Parallel group, Multicenter Efficacy and Safety Study of "…" pMDI 2 x 160/4.5 µg & 80/4.5 µg b.i.d. Compared to … TBH, … pMDI (& the combination & Placebo in COPD Patients. 6 Subjects. AstraZeneca, Protocol #D5899C00002.
2004	An epidemiologic study of Xolair® (…): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (Excels). 30 Subjects. Genentech, Inc., Protocol #Q2948g.
2004	A randomized, double-blind, placebo-controlled, parallel group, multi-center, multiple dose (7 days) dose ranging study, to assess the efficacy and safety of 4 doses of "XXXX" (50, 100, 200 & 400 µg) delivered via a multiple dose inhaler and 1 dose of "XXXX" (400 µg) delivered via a single dose inhaler in patients with chronic obstructive pulmonary disease (COPD). 6 Subjects. Novartis, Protocol #2205.
2004	An epidemiologic study of Xolair® (…): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (Excels). 30 Subjects. Genentech, Inc., Protocol #Q2948g.
2004	A randomized, controlled study of … (250 mcg. and 500 mcg.) versus placebo in patients with asthma. 12 Subjects. Altana, Protocol No. BY217-M2-023.
2004	A Four-Week, Double-Blind, Placebo-Controlled Exploratory Evaluation of $FEV_{1.0}$ Changes and Safety of ONO-6126 in Patients

	with Chronic Obstructive Pulmonary Disease (COPD). 5 Subjects. ONO Pharma USA, Inc., (A subsidiary of Ono Pharmaceutical Co., Ltd. Protocol No. ONO-6126POU011.
2003	A randomized, double-blind, active-controlled, parallel-group, single-dummy, multicenter, 12 week study to assess the efficacy and safety of … pMDI 160/4.5 mcg. x 2 actuations once-daily (QD) compared to … pMDI 80/4.5 mcg. x 2 actuations QD, … pMDI 80/4.5 mcg. x 2 actuations twice-daily (BID) and to … pMDI 160 mcg. x 2 actuations QD in asthmatic subjects 12 years of age or older. 10 Subjects. AstraZeneca, Protocol No. D5896C00001.
2003	A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of … (160/4.5 mcg.) versus its Mono-Products (… and …) in Adolescents (≥ 12 Years of Age) and Adults with Asthma. 10 Subjects. AstraZeneca, Protocol No. SD-039-0717.
2003	A Phase IIIa, multi-center, randomized, double-blind, parallel-group, placebo-controlled study on the efficacy and safety of … HCl 180 mg. once daily in chronic idiopathic urticaria. 5 Subjects. Aventis Pharmaceuticals, Protocol # M016455A/4121.
2002	An Efficacy and Safety Study of …, … … and Placebo in Subjects Twelve Years of Age and Older with Asthma. 10 Subjects, Sepracor, Inc., Protocol No. 051-353.
2002	A Double-Blind, Placebo and Active-Controlled, Parallel Group Study of … Administered to Subjects with Seasonal Allergic Rhinitis. 20 Subjects, Sepracor, Inc., Protocol No. 110-073.
2002	A Long Term Safety Study of … and … … in Subjects Twelve Years of Age and Older with Asthma. 10 Subjects, Sepracor, Inc., Protocol #051-356.
2002	A Multicenter, Open-Label, Randomized, Active-Controlled, Parallel Group Chronic Safety Study of … in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease. 10 Subjects, Sepracor, Inc., Protocol 091-060.
2002	A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel Group Study of … in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease. 10 Subjects, Sepracor, Inc., Protocol 091-051.
2002	A Phase II, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Arm Dose Comparison Study of the Efficacy and Safety of Oral 25 mg, 50 mg, 75 mg … and Placebo in the Treatment of Patients with Chronic Obstructive Pulmonary

	Disease. 10 Subjects, Otsuka Maryland Research Institute, Protocol 197-01-210.
2002	A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of … 120 MG BID In Patients With Mild To Moderate Persistent Asthma. 12 Subjects, Aventis Pharmaceutics, Inc., Protocol M016455P/3002.
2002	A Multicenter, Double-Blind, Randomized Parallel Study Comparing the Efficacy and Safety of … 120 mg BID, … 240 mg QD, and Placebo in Subjects with Perennial Allergic Rhinitis. 15 Subjects, Aventis Pharmaceuticals, Inc., Protocol M016455M/3001.
2002	An evaluation of the effectiveness of … … (… inhalation suspension) versus … (… sodium) in children 2-8 Years Old With Asthma Requiring Controller Therapy. 10 Subjects, AstraZeneca., Protocol DX-RES-2103.
2002	A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of … (80/4.5 mcg.) versus its Mono-Products (… and …) in Children (=6 Years of Age) and Adults with Asthma--Spruce 80/4.5. 10 Subjects, AstraZeneca, Protocol No. SD-039-0716.
2002	A Double-Blind, Placebo-Controlled Study of the Effect of ... in Subjects with Perennial Allergic Rhinitis. 10 Subjects, Schering-Plough Research Institute, P02772.
2002	A Phase III Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Placebo-Controlled, Efficacy and Safety Study of ... MDI 400 μG/Day, 800 μG/Day (Ex-Valve) and ... MDI (... ...) 880 μG/Day (Ex-Actuator) Administered Twice Daily for 12-Weeks in the Treatment of Severe Persistent Asthma in Adolescents and Adults. 16 Subjects, Aventis, XRP1526B-323.
2002	A Multicenter, Double-Blind, Randomized, One Year, Long-Term Safety Study of ... 400 μG/Day to 800 μG/Day (Ex-Valve) or ... 320 μg/Day to 640 μg/Day (Ex-Actuator) Metered Dose Inhaler Administered Twice Daily for the Treatment of Severe Persistent Asthma in Adolescents and Adults. 16 Subjects, Aventis, XRP1526B-323LT.
2002	A Study to Determine the Efficacy and Safety of .... in the Symptomatic Treatment of Chronic Urticaria. 12 Subjects, Sepracor, 110-050.

2002	A Multicenter, Open-Label, Randomized, Parallel Group Study to Assess the Long-Term Safety Performance of ... Compared to ... in Subjects with Asthma. 12 Subjects, Aventis Pharmaceuticals, Inc., M016455P/3003.
2002	A Randomized, Multicenter, Placebo-Controlled Parallel Group Study of Four Months Duration Per Patient to Evaluate the Safety and Efficacy of Treatment with 24 μg b.i.d. and 12 μg b.i.d. ... , Double-Blind, and 12 μg b.i.d. ... with Additional On-Demand ... Doses, Open-Label, in Adolescent and Adult Patients with Persistent Stable Asthma. 12 Subjects, Novartis, FOR25802307.
2001	Placebo-Controlled Efficacy and Safety Study of … ... Administered Via Dry Powder Inhaler in the Treatment of Asthma in Children Previously Maintained On Inhaled Corticosteroids. 9-12 Subjects, Schering-Plough Research Institute, P01431-12.
2001	An Observational Study of the Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (Tenor). 20 Subjects, Genentech, Inc., Q2196n.
2001	A Phase III Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety and Dose Response Study of ... Metered Dose Inhaler 100 μG/Day, and 400 μG/Day (Ex-Valve) Administered Once Daily for 12-Weeks in the Treatment of Mild to Moderate Persistent Asthma in Adolescents and Adults. 16 Subjects, Aventis, XRP1526B – 322.
2001	A Phase III Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety and Dose Response Study of ... Metered Dose Inhaler 50 μG/Day, and 100 μG/Day, and 200 μG/Day (Ex-Valve) Administered Once Daily for 12-Weeks in the Treatment of Children with Persistent Asthma. 16 Subjects, Aventis Pharmaceuticals, XRP1526B – 342.
2001	A Multicenter, Randomized, Controlled, Open-Label Study to Evaluate the Safety of ... in Moderate to Severe, Persistent Asthma Subjects Already Treated with Other Therapies (Alto). 12 Subjects, Genetech, Inc., Q2143g.
2001	A Stratified, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Trial Evaluating the Safety and Efficacy of the ... ... /... ... Combination Products 100/50 mcg Once Daily Versus ... ... 100 mcg Once Daily and Placebo in Symptomatic Pediatric Subjects (4 - 11 Years) With Asthma. 7 Subjects, GlaxoSmithKline, SAS30021.
2001	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Trial Evaluating the Safety and Efficacy of the ... .../... ...Combination Product 250/50 mcg Once Daily Versus ... .../... ...

	Combination Product 100/50 mcg Twice Daily versus ... .../... 250 mcg. Once Daily Versus Placebo in Symptomatic Adolescent and Adult Subjects with Asthma That is Not Controlled on Short Acting $Beta_2$ Agonists Alone. 12 Subjects, GlaxoSmithKline, SAS30022.
2001	A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel Group, 16-Week Comparison of Asthma Control in Adolescents and Adults Receiving Either ... .../... ...Combination Product 100/50 mcg BID, .../... 100 mcg BID, .../... 50 mcg BID, or Oral ... 10 mg QD. 10 Subjects, GlaxoSmithKline, SAS40036.
2001	A 12-Week Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study in Children (Aged 5-12, inclusive) with Persistent Asthma Evaluating the Safety, Efficacy, and Pharmocokinetics of ... (... ...) 10 μg b.i.d. Delivered by the Multi-Dose Dry Powder Inhaler (MDDPI) Versus Placebo. 12 Subjects, Novartis, .../FOR258. Protocol # CFOR258FO604.
2001	A 12-Week Randomized, Multicenter, Double-Blind, Double-Dummy, Placebo and Active Controlled, Parallel Group Study Evaluating the Safety and Efficacy of ... ... (10 μg b.i.d.) Delivered by the Multi -Dose Dry Powder Inhaler (MDDPI) Versus Placebo versus ... pMDI q.i.d. in Patients with Persistent Asthma. 12 Subjects, Novartis, .../FOR258. Protocol # CFOR258F2302.
2001	A Double Blind, Placebo-Controlled Study of ... in Subjects With Seasonal and/or Perennial Allergic Rhinitis and Concomitant Asthma. 12 Subjects, Sepracor, 110-060.
2000	Phase III, An Open, Non-Comparative MultiCentre Study to Assess the Efficacy and Safety of Oral ... 125 mg Twice Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis in Adults, SmithKline Beecham, BRL-025000/551.
2000	Phase III, A Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of ... ... Inhalation Powder (250 mcg QD) and Placebo in Subjects At Least 12 Years of Age with Chronic Asthma Currently Receiving Short Acting Beta Agonist Alone, Glaxo Wellcome, FPD40009.
2000	Phase III, An Open, Non-Comparative MultiCentre Study to Assess the Efficacy and Safety of Oral ... 125 mg Twice Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis in Adults, SmithKline Beecham, BRL-025000/551.
2000	A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of …-…vs. ...-… (… 12 Hour) vs. Placebo in the Treatment of Subjects Twelve Years

and Older with Seasonal Allergic Rhinitis. 36 Subjects, Pfizer, Inc., A3771001.

2000 A Randomized, Double Blind, Placebo Controlled, Parallel-Group. Multiple-Dose. Multicenter 12-Week Study to Compare the Safety and Efficacy of … ... via the "To-Be-Marketed" … Dry Powder Inhaler to … Metered-Dose Inhaler in Patients with Asthma. 12 Subjects, Dura Pharmaceuticals, Inc., DPIBDP-06.

2000 A Study of the Effect of … 5 mg and … 240 mg on Nasal Stuffiness in Subjects With Seasonal Allergic Rhinitis. 30 Subjects, Schering-Plough Research Institute, P01434-26.

2000 Efficacy and Safety of Two Formulations of SCH 483 5/240 mg Compared to …5 mg and … 240 mg QD Sustained Release, in the Treatment of Subjects with Seasonal Allergic Rhinitis. 32 Subjects, Schering-Plough Research Institute, P01884-20.

2000 Efficacy and Safety of … 5 mg Tablet in the Treatment of Subjects 12 to 17 Years of Age with Seasonal Allergic Rhinitis. 12 Subjects, Schering-Plough Research Institute, P01376-28.

2000 Efficacy and Safety of Combination …/… QD vs. Its Components in the Treatment of Subjects With Seasonal Allergic Rhinitis. 32 Subjects, Schering-Plough Research Institute, CS-203-22.

2000 A Randomized, Double Blind, Parallel Group, Placebo Controlled, 12-Week Trial of Inhaled ….... 88 mcg BID, 220 mcg BID, and 440 mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Inhaled Corticosteroid Therapy. 5 Subjects, Glaxo Wellcome, Inc., FAP30007.

2000 A Randomized, Double Blind, Parallel Group, Placebo-Controlled, 12-Week Trial of Inhaled … ... 88 mcg BID, 220 mcg BID, and 440 mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy. 5 Subjects, Glaxo Wellcome, Inc., FAP30008.

2000 A Double Blind, Placebo Controlled, Long Term Growth Study of HFA … in Children with Mild Asthma. 8 Subjects. Forest Laboratories, Inc., ANC-MD-07-000.

2000 A Randomized, Double-Blind, Parallel Group, Comparative Trial of …/… ... Combination Product 50/100 mcg DISKUS Inhaler BID versus … ... 250 mcg DISKUS Inhaler BID in Adolescents and Adults with Moderate Persistent Asthma. 12 Subjects, Glaxo Wellcome, Inc., SAS40026.

2000	A Randomized, Double-Blind, Double Dummy, Parallel Group, Comparison of … ... Inhalation Powder (50 mcg BID) via DISKUS with Oral … (5 mg QD) Chewable Tablets in Children 6-12 years of Age with Persistent Asthma. 8 Subjects, Glaxo Wellcome, Inc., FPD40012.
2000	A Randomized, Double-Blind, Parallel Group Study Evaluating the Protective Effects of the … .../… ... Combination Product (50/250 mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma. 6 Subjects, Glaxo Wellcome, Inc., SAS40025.
2000	A Randomized, Double-Blind, Parallel Group Study Evaluating the Protective Effects of the … .../… ... Combination Product (50/100 mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma. 6 Subjects, Glaxo Wellcome, Inc., SAS40024.
1999	A Dose Ranging Study of ... HFA-227 Nasal Aerosol in the Treatment of Patients with Seasonal Allergic Rhinitis, Schering Plough C97-297 (Spring 1999).
1999	The Evaluation of ... 30 mg and ... when Administered to Subjects with Seasonal Allergic Rhinitis, Sepracor 110-032 (Fall 1999).
1999	12 Weeks, Phase III, A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Study of ... ... 44 mcg BID and 88 mcg BID Delivered via CFC MDI and a Valved Holding Chamber with Facemask in Subjects With Asthma Age 24 Months to 47 Months, Glaxo Wellcome, FMS 30058.
1999	Phase IV, A Randomized, Double-Blind Multicenter Study to Evaluate the Effect of Adding Either … … or … … to Inhaled … in Adult Asthmatics, Merck & Co., Inc., 120-00.
1999	Phase III, Efficacy and Safety of ..., BID, vs. its Components in the Treatment of Subjects with Seasonal Allergic Rhinitis, Schering-Plough, P00355.
1999	12 Weeks, Phase III, Comparison of Daily Doses of 100 mcg and 200 mcg ... ... in the Autohaler™ Device Versus Placebo in Pediatric Patients with Symptomatic Asthma, 3M, 1343-BRON.
1999	Phase III, Efficacy and Safety of SCH 34117 in the Prophylaxis of Subjects with Seasonal Allergic Rhinitis, Schering-Plough, P00375.

1999	12 Months, Phase III, A Safety Study of ... QD in Subjects with Perennial Allergic Rhinitis/Seasonal Allergic Rhinitis, Sepracor, 110-029.
1999	Phase IV, A Randomized, Double-Blind, Parallel Group Comparison Study of Inhaled … Propionate (88 mcg BID) Versus … Sodium (10 mg QD) in Subjects Currently Receiving Beta Agonists Alone, Glaxo Wellcome, FLTA4038.
1999	12 Weeks, A Randomized, Double-Blind, Double-Dummy, Parallel Group, Comparative Trial of .../... ... Combination Product 50/100 mcg BID Via the DISKUS Inhaler Versus Oral ... 10 mg QD in Adolescents and Adults with Persistent Asthma, Glaxo Wellcome, SAS 40021.
1999	Phase III, Efficacy and Safety of SCH 34117 in Patients with Perennial Allergic Rhinitis, Schering-Plough, P00218.
1999	12 Weeks, Phase III, A Multi-Center, Randomized, Double-Blind, Double Dummy, Parallel Group, Active Control Comparison of .../... ... Combination Product (50/100 mcg BID) via the DISKUS Inhaler with ... ... (100 mcg BID) via the DISKUS plus Oral ... (10 mg QD) in Adults and Adolescents with Persistent Asthma Experiencing Symptoms on Inhaled Corticosteroid Therapy, Glaxo Wellcome, SAS40018.
1999	Phase III, An Open-Label Extension to Provide Continuation of rhuMAb-E25 Treatment to Children with Allergic Asthma Who Participated in the One-Year Study (rhuMAb-E25 Protocol No. 01 010), Novartis, Extension 1, Protocol No. 01 010.
1999	12 Weeks, Phase III, Double-Blind, Placebo-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of .../ ... ... Combination in GR106642X MDI, 50/250 mcg BID, and ... in Propellant 11/12 MDI, 50 mcg BID, and ... ... in Propellant 11/12 MDI, 250 mcg BID, and Placebo in Propellant GR106642X MDI in Adolescent and Adult Subjects with Asthma, 12 patients, Glaxo Wellcome SAS30004.
1999	14 Weeks, Phase III, A Multicenter, Double-Blind, Placebo Controlled, Randomized Parallel Trial Evaluating the Efficacy and Safety of HFA ... vs. CFC ... in Pediatric Patients with Mild to Moderate Asthma, 10 pediatric patients, Forest ANC-MD-03-000.
1999	7 Weeks, Phase III, Safety and Efficacy Study of HFA-134a ... ... Delivered form a Press-and Breathe MDI, HFA-134a ... ... Delivered from the Autohaler™ Inhalation Device, and HFA-Placebo in Patients with Asthma, 12 patients, 3M 1273 BRON 1332-SILV.

1999	14 Weeks, Phase III, A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of ... ... Inhalation Powder (50 mcg BID) with Oral ... (10 mg QD) in Subjects with Persistent Asthma Symptomatic on Concomitant Inhaled Corticosteroid Therapy, 12 patients, Glaxo Wellcome SMS40004.
1998	20 Weeks, Phase II, A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of ... Calcium Nasal Spray, 5% for the Prevention of Recurrent Acute Bacterial Sinusitis, 16 patients, SmithKline Beecham 4910F/149.
1998	26 Week, Phase III, Randomized, Parallel-Group, Open-Label Multicenter Clinical Study Comparing the Safety, Efficacy, Quality of Life and Socioeconomic Variables of Twice Daily ... Powder (12 μg bid) to Twice Daily ... (50 μg bid) Administered for Six Months to Adult Subjects with Reversible Obstructive Airway disease (ROAD), 5 patients, Novartis 073.
1998	12 Weeks, Phase IV, A Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Treatment of Seasonal Allergic Rhinitis (SAR) in Subjects with Comorbid Asthma and History of Seasonal Exacerbations of Asthma on Medical Resources Utilization (for Asthma and SAR), 8+ patients, Integrated Therapeutics P97-293.
1998	26 Weeks, Phase III, A Randomized, Double-Blind, Parallel-Group Trial of Inhaled ... ... /GR106642X 220 BID and 440 mcg BID in Adolescent and Adult Subjects with Asthma, 10 patients, Glaxo Wellcome FAP30001.
1998	14 Weeks, Phase III, Placebo-Controlled Efficacy and Safety Study of ... ... HFA-227 Metered Dose Inhaler (MF-MDI) in the Treatment of Asthma in Children Previously Maintained on Inhaled Corticosteroids, 12 pediatric patients, Schering Plough C98-005.
1998	9 Weeks, Phase III, A Double-Blind, Randomized, Parallel Study Comparing the Efficacy and Safety of ... HCl 120 MG Q.D., 180 MG Q.D., ... HCl 10 MG Q.D., And Placebo Q.D. In The Treatment Of Perennial Allergic Rhinitis, 24 patients, HMR MO16455M/3097.
1998	24 Weeks, Phase III, A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the Diskus Formulations of ... 50 mcg BID ... ... 500 mcg BID Individually and in Combination as Compared to Placebo in COPD Subjects, 12 patients, Glaxo Wellcome SFCA3006.

1998	12 Weeks, Phase III, Randomized, Double-Blind, Between-Patient Trial Comparing Two Doses of Inhaled ... ... Dry Powder (12 and 24 μg b.i.d.) with Placebo and ... ... MDI (40 μg q.i.d.) for 12 weeks in Patients with Chronic Obstructive Pulmonary Disease, in Terms of Clinical Efficacy, Tolerability and Quality of Life, 12 patients Novartis-056.
1998	5 Weeks, Phase III, The Evaluation Of Three ... Doses (30 mg, 60 mg, 90 mg) and ... When Administered To Subjects With Seasonal Allergic Rhinitis, 40 patients Sepracor 110-024.
1998	9 Weeks, Phase III, Dose Response Comparison of HFA-134a ... Autohaler Inhalation Device with HFA-134a ... Press & Breath MDI in Patients With asthma, 12 patients, 3M 1273-BRON.
1998	17 Weeks, Phase III, A Multicenter, Double-Blind, Randomized Study Comparing the Effect of Clinical Concomitant ... and ..., with ..., ... and Inhaled ... in with Chronic Asthma, 12 patients, Merck MK-074-00.
1998	One-Year, Phase III, Double-Blind Study of the Effects of ... ... Dry Powder Inhaler (MF DPI) vs. Placebo on Growth of Children with Asthma, 12 pediatric patients, Schering Plough C97-384.
1998	12 Week, Phase II, Study to evaluate the efficacy and safety of ... ... Dry Powder Inhaler (MF DPI) in the treatment of asthma in children previously maintained on inhaled corticosteroids, 12 -18 patients, Schering Plough C97-300.
1998	3 Weeks, Phase III, Study to evaluate the effectiveness and safety of ... (SCH 34117) in reducing allergy symptoms due to spring tree and grass allergens, 36 patients, Schering Plough C98-001-10.
1998	2 Weeks, Phase III, Comparison of the safety and efficacy of ... vs. ... (...) in the treatment of seasonal allergic rhinitis, 36 patients, Integrated Therapeutics P97-345-10.
1998	14 Week, Phase II/III, Parallel-group, safety, efficacy, and dose response of ... HFA-134a inhalation aerosol administered once daily in treatment of mild and moderate persistent asthma, 16 patients, Rhone-Poulenc Rorer RG5016Y-204.
1998	52 Week, Phase III, Trial to access safety and tolerability, steroid reduction, pharmacokinetics, and pharmacodynamics of subcutaneous rhuMAb-E25 in children with allergic asthma requiring daily inhaled corticosteroids, 12 pediatric patients, Novartis rhuMAb-E25 01010.

1998	9 Week, Phase III, Study to compare effectiveness, and tolerability of dosing with ... versus ... in subjects with mild-to-moderate asthma, 16 patients, Sepracor 051-027.
1998	2 Weeks, Phase III, Study to compare the safety and efficacy of ... with ... for the treatment of acute bacterial maxillary sinusitis, 12 patients, Bayer 100107.
1998	8 Weeks, Phase III, Study of the safety and effectiveness of ... (...), 4 puffs at bedtime using the AeroChamber ® in patients with mild to moderate asthma, 5 patients, Forest AER-MD-07-000.
1998	52 Weeks, Phase III, open controlled extension to the chronic asthma study comparing ... with placebo in 2 to 5 year old patients (open extension to protocol 072-02), Merck 072-10.
1998	15 Weeks, Phase III, Study to determine the safety and tolerability of ... in the treatment of 2 to 5 year old children with asthma, 6 pediatric patients, Merck 072-02.
1998	18 Weeks, Phase III, Comparative trial of ... (... ...) using a non-CFC propellant in reducing the need for oral prednisone in adolescent and adult subjects, 6 patients, Glaxo Wellcome FLTA 3022.

1997 - 1998	18 Weeks, Phase III, Study to evaluate the safety and efficacy of ... ... HFA-227 Metered Dose Inhaler in subjects previously maintained on inhaled corticosteroids, 20 patients, Schering Plough C97-227-09.
1997 - 1998	7 Week, Phase III, Study comparing the use of ... ... (... Inhalation Aerosol) to ... (... Tablets) in patients who are currently receiving low dose inhaled corticosteroids, 16 patients, Glaxo Wellcome FLTA4034.
1997	6 Week, Phase III, Study comparing the use ... ... (...) and ... (...) in the treatment of mild to moderate asthma, 8 patients, Glaxo Wellcome SLGA5025.
1997 - 1998	3 Week, Phase III, Efficacy and safety of dosage strengths of ... ... Nasal Spray in the treatment of Acute Sinusitis, 18 patients, Schering Plough C97-251-28.
1997	5 Week, Phase III, Dose ranging, comparative trial of ... in the treatment of patients with seasonal allergic rhinitis, 40 patients, Schering Plough 110-008.
1997	4 Week, Phase IV, Study of the efficacy and safety of Zyrtec ® (Cetirizine HCI) syrup on children with hayfever, 5 patients Pfizer L-0350.
1997 - 1998	52 Week, Phase III, Comparison Trial of ... dry powder capsules by single dose in children 6-12 in need of daily treatment with inhaled bronchodilators and anti-inflammatory treatment, 18 pediatric patients, Novartis CGP 25827A.
1997 - 1998	26 Week, Phase III Extension, Comparing preference for ... ... Tablets or ... ... Aerosol MDI in children 6-11 with chronic asthma, 6 pediatric patients, Merck 065-10 (Safety Extension) 065-20 (Safety Extension # 2).
1997	52 Week, Phase III Study of the efficacy, and safety of ... Nasal Spray in prevention of recurrent sinusitis, 12 Patients, Schering Plough C96-252-07.
1997	12 Week, Phase III Cross-Over study comparing preference for ... ... Tablets or ... ... Aerosol MDI in children 6-11 with chronic asthma, 6-12 Pediatric Patients, Merck 065-01/SNG 386.
1997	6 Week, Phase III Comparison study of four dosage strengths of ... ... (20, 60, 120 & 240 MG BID) in treatment of chronic urticaria, 10 Patients, HMR 016455PR0067.

1997	52 Week, Phase III Comparison Trial of ... dry powder, capsules by single dose inhaler vs. inhaled bronchodilators, 10 - 12 Pediatric Patients, Novartis CGP 25827A.
1997	20 Week, Phase III Trial of the efficacy of oral ... in Controlled-Release and Immediate Release in patients with moderate asthma, 10 patients, Abbott M95-337.
1997	14 Week, Phase III Study of ... ... Dry Powder compared to ... ... previously on Inhaled Corticosteroids, 16 Patients, Schering Plough C96-168.
1997	6 Week, Phase III Oral inhalation device study, diskus vs. metered dose inhaler with ..., 12 Pediatric Patients, Glaxo Wellcome SALA3008.
1996-1997	12 Week, Phase III Parallel group study of twice daily oral suspension ..., 12 Patients, SmithKline Beecham SB205312/070.
1996-1997	16 Weeks, Phase III, Open Label controlled extension to oral leukotriene antagonist study, 3 Pediatric Patients, Merck MK-0476-10, MK-0476-12.
1996-1997	52 Week, Phase III Open Label, controlled extension to oral leukotriene antagonist study, 1 Pediatric Patient, Merck MK-0476-14.
1996-1997	52 Week, Phase III Evaluation of long term safety of ... ... Dry Powder, 12 Patients, Schering Plough C96-136-09.
1996-1997	24 Week, Phase III Trial of ... ... plus ... ... vs. ... ... alone in subjects not well controlled on ... ..., 16 patients, Glaxo Wellcome SLGA5021.
1996-1997	14 Week, Phase III Trial of inhaled ... and ... individually and in combination in subjects with asthma, 16 patients, Glaxo Wellcome SFCA3003.
1995 -1997	18 Week, Phase III Parallel study of CFC and Non-CFC formulations of ... (... ...) MDI, 18 patients, Fisons/RPR CR2509.
1995 - 1997	52 Week, Phase III Open Label, long-term study of Non-CFC formulation of aerosol ... ..., 5 patients, Fisons/RPR CR2506.
1995 -1996	52 Week, Open Label, long term study of safety, and efficacy of twice daily oral peptidoleukotrienes agonist, 12 patients, SmithKline Beecham B205312/087.
1996	8 Week, Phase III Trial of ... in the reversal of bronchoconstriction and in the management of asthma, 12 patients, Sepracor 051-024.

1996	12 Week, Phase III Crossover study comparing the combination ... to ... to ... in Patients in chronic asthma, 8 patients, Merck MK-0476-062.
1996	14 Week, Phase IV Study of ... and ... ... alone and in combination vs. placebo, patients with seasonal allergic rhinitis and headache, 34 patients, Schering Plough C96-051-09.
1996	52 Week, Phase III Open-Label comparison of ... (...) ... Pump Spray, vs. ... in treatment of children with Perennial Allergic Rhinitis, 6 pediatric patients, Astra 05-346 Rhinocort.
1996	16 Week, Phase III Study of the effects of oral leukotriene in patients with asthma & seasonal allergic rhinitis in comparison to patients taking inhaled ..., 12 patients, SmithKline Beecham SB 205312/080.
1996	24 Week, Post-marketing comparison of adding Serevent ® vs. double dose of Beclovent ® in asthmatic patients symptomatic on their existing corticosteroids, 9 patients, Glaxo Wellcome SLGA5017.
1996	14 Week, Phase III Double-Blind parallel group study of inhaled ... ... and ... via metered dose inhaler in asthmatic subjects previously treated with ... ..., 16 patients, Glaxo Wellcome FLTA4015.
1996	11 Week, Phase III Oral leukotriene antagonist safety and efficacy study, 10 pediatric patients, Merck MK-0476-049.
1996	14 Week, Phase III Double-Blind comparative of inhaled ... ... via the Diskus twice daily vs. ... ... ® via Rotahaler four times daily, 16 patients, Glaxo SLGA3014.
1995 - 1996	52 Week, Phase III, Open Label, Long Term study of safety and efficacy of Oral SB 205312 in patients with asthma, 5 patients, SmithKline Beecham SB205312/022.
1995 - 1996	28 day, Phase III Parallel group pilot trial evaluating the safety and efficacy of ... ... and ... ... individually and in combination in patients with asthma, 18 patients, Glaxo FLTA3015.
1995 - 1996	14 Week, Phase III Comparative trial of ... via Diskus and ... via metered dose inhaler, 12 patients, Glaxo SLGA3011.
1995 - 1996	30 Week, Phase III Post marketing parallel group trial of Salmeterol Xinafoate BID, and Beclomethasone Dipropionate QID and placebo in mild to moderate asthmatics, 15 patients, Glaxo SLGA5015.

1995 -1996	52 Week, Phase III Trial to access long-term safety and efficacy of ... via the diskus, 18 patients, Glaxo SLGA3009.
1995 - 1996	10 Week, Phase III Parallel group to evaluate the safety efficacy of twice daily, oral peptiodoleukotrienes antagonist study in mild to moderate asthmatics, 12 pediatric patients, SmithKline Beecham SB205312/084.
1995 - 1996	16 Week, Phase III premarketing oral peptidoleukotriene agonist dosing study, 12 patients, Abbott M94-216
1995	6 Week, Phase III premarketing comparison of CFC and Non-CFC with Beclomethasone, 12 patients, 3M 1081 BRON.
1995	14 Week Phase III Parallel group trial of ... ... via the multi-dose inhaler vs. ... ... via Diskhaler ®, 20 pediatric patients, Glaxo FLTA-2006.
1994 - 1995	12 Month, Phase III pre-marketing four times daily oral ... study, 15 patients, Abbott M94-199.
1994 - 1995	18 week, Phase III Double-Blind, placebo controlled, parallel study of safety and efficacy twice daily oral leukotriene agonist study, 20 Patients, SmithKline Beecham SB205312/010.
1994 - 1995	15 Week Phase III Comparison Trial of ... ... combined with investigational propellant vs. ..., 17 patients, 3M 1129 BRON.
1994 - 1995	27 Week Phase III Comparative Trial of Inhaled ... ... Rotadisks ® via diskhaler vs. ... oral inhaler, 20 patients, Glaxo FLD-401.
1994	4 Week Phase III Comparative Trial of three different doses of ... tablets in treatment of seasonal allergic rhinitis, 40 patients, Schering Plough Loratadine C93-145-06.
1994	8 Week, Phase III Comparative Trail of ... ... via multi-dose powder inhaler vs. ... via diskhaler, 15 patients, Glaxo SLGA2004 12 hr/day.
1993-1994	52 Week Phase III Parallel Group Pediatric Inhaled ... ... via diskhaler vs. Placebo, 23 patients, ... /Rotadisk via diskhaler, Glaxo FLD-220.
1993-1994	9 Week Phase III Parallel group trial of ... ... both as an inhaled and oral corticosteroid study, 38 patients, ... /Rotadisk via diskhaler, Glaxo FLD-230.

1993	4 Week Phase III Comparative Study of ... vs. .../... ... in treatment of Acute Maxillary Sinusitis, 9 patients, ... Bristol-Myers Squibb AI414-144.
1993	Week Phase III Trial of Aqueous Nasal Spray in adult patients with ragweed allergic rhinitis, 60 patients, ... RPR RG5029Y.
1993	3 Week, Phase III An evaluation of ... ... inhalation aerosol in symptomatic patients with mild to moderate asthma, 5 patients, ... Fisons 1231-2197.
1993	2 Week, Phase III Safety and efficacy trial of ... ... vs. ... tablet in patients with seasonal allergic rhinitis, 45 patients, ... Schering Plough C92-258-04.
1993	4 Week, Assessment of patients requiring an Inhaled Beta-2 Adrenergic Agonist, 10 patients, ... Autohaler 3M.
1992 -1993	13 Week, Phase III Parallel group evaluation of ... Powder delivered via Diskhaler vs. ... Powder via the Rotahaler, 20 pediatric patients, Glaxo VRD-302.
1992 -1993	8 Week, Phase III Dosing trial of inhaled steroid, ... , in patients ith moderate asthma, 35 patients, ... RPR RG5016-403.